Mitotech discusses SkQ1 and Dry Eye Disease in a recent Fierce Biotech article
Feb 10, 2017
Natalia Perekhvatova, the CEO of Mitotech S.A., discussed particulars of the mechanism of action of SkQ1 in treating Dry Eye Disease in a recent article by Fierce Biotech. You can access the full article here:
News & Events
- Mitotech Completes First Patient Visit in VISTA-1 - Phase 2b/3 Clinical Study of SkQ1 for Dry Eye Disease
- Mitotech Initiates Phase 2b/3 Clinical Trial of SkQ1 Ophthalmic Solution in Patients with Dry Eye Disease in a Co-Development Effort with Essex Bio-Technology
- Mitotech partners with Essex Bio-Technology for a late-stage clinical program in Dry Eye Disease
- Mitotech announces new Dry Eye data set supporting SkQ1’s novel mechanism of action
- Mitotech's SkQ1 improved visual acuity in Leber's Hereditary Optic Neuropathy (LHON) patients
- Mitotech’s SkQ1 and its potential for treating age-related disorders discussed in Fierce Biotech publication
- Mitotech’s lead compound significantly increased lifespan of rapidly aging mice